Company intelligence / Profile preview

OPUS project

Raleigh, North Carolina, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Opus Genetics is a clinical-stage gene therapy company dedicated to developing treatments for rare, inherited retinal diseases. Founded by the Foundation Fighting Blindness and leading retinal experts, the company focuses on addressing unmet medical needs in patients with genetic mutations that cause blindness. Their lead program, OPGx-LCA5, is an adeno-associated virus (AAV) based gene therapy currently in clinical trials for Leber congenital amaurosis 5. In 2024, the company was acquired by Ocular Therapeutix to bolster their regenerative medicine and gene therapy pipeline.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAdeno-associated virus (AAV) vector
Industry: Biotech

Partnerships

Foundation Fighting BlindnessNational Eye Institute

Beyond the preview

Go deeper on OPUS project.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPUS project.

Explore the full profile